Sangui BioTech:

- Sales of USD 47,186 in the first nine months
- Costs and loss is further reduced

Witten, May, 30 2017: In the first nine months of fiscal year 2017 (to 31/03/2017) Sangui BioTech International Inc. achieved revenues from royalty income and product sales of USD 47,186. In the same period of the previous year the comparable revenue amounted to USD 37,005. Due to increased revenues of the wound spray Granulox, the resulting royalty income in the first three quarters increased by 28% compared to the same period of the previous year. After a strong year-end business in the second quarter, revenues in the third quarter were higher than in the same quarter of the previous year.

The cost - cutting - and liability - protection program adopted during the last year also had an effect in the reporting period: In the first three quarters of the year, operating business expenses were reduced by a further USD 17,051 or 5% to USD 340,792. As a result of this, the operating loss of the first nine months decreased compared to the prior year by USD 26.841 to USD 294,269. Accordingly, the cash position of the Company during the reporting period improved.

The sales of Granulox are subject to seasonal fluctuations. Thus, a strong end-of-year business was recorded in the previous quarter. In the quarter under review, sales of Granulox and royalty income did not reach the level of the previous quarter as planned. For the full year 2017, however, the company is still expecting the increase in sales of Granulox and corresponding royalty revenues.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.